Hepion Pharmaceuticals’ (NASDAQ:HEPA) comprehensive review of studies on the role of cyclophilins in non-alcoholic steatohepatitis (NASH) and NASH-related liver disease has been published in peer-reviewed journal...
iBio (NYSE AMERICAN:IBIO) filed a motion in the Court of Chancery of the State of Delaware to initiate new litigation against Fraunhofer-Gesellschaft through an amended complaint. The new motion asserts that depositions...
X4 Pharmaceuticals (NASDAQ:XFOR) initiated a Phase 1b trial of mavorixafor in combination with ibrutinib, a Burton tyrosine kinase (BTK) inhibitor, for the treatment of Waldenström’s macroglobulinemia (WM). WM is a rare...
Kate DeVarney, EVP and CSO of Titan Pharmaceuticals (NASDAQ:TTNP), was elected to the board at the company’s annual meeting. Dr. DeVarney, a clinical neuropsychologist by training, joined Titan in January...
iBio (NYSE AMERICAN:IBIO) entered into a collaboration with EdgePoint AI, a division of Mateon Therapeutics (OTCQB:MATN), to deploy EdgePoint’s proprietary artificial intelligence/blockchain-driven vision system for...
Lexicon Pharmaceuticals (NASDAQ:LXRX) reported topline data from its Phase 3 study of sotagliflozin for the treatment of Type 2 diabetes (T2D). Sotagliflozin is an oral dual inhibitor of sodium-glucose co-transporter...
Aravive (NASDAQ:ARAV) has begun enrolling patients in its Phase 2a clinical trial of AVB-500 in patients with kidney fibrosis, specifically immunoglobulin A nephropathy (IgAN). IgAN occurs when an antibody called...
Arrowhead Pharma (NASDAQ:ARWR) dosed the first patient in its Phase 2 clinical study of ARO-AAT for the treatment of alpha-1 antitrypsin deficiency (AATD)-associated liver disease. AATD is a rare genetic disorder where...
Concert Pharmaceuticals (NASDAQ:CNCE) completed its open-label trial comparing once-daily versus twice-daily dosing of CTP-543 in alopecia areata patients. Alopecia areata is an autoimmune disease that causes partial or...
Selecta Biosciences (NASDAQ:SELB) completed enrollment in its Phase 2 COMPARE trial of SEL-212 for the treatment of chronic refractory gout. SEL-212 is designed to sustain control of serum uric acid (SUA) levels in...